Last Updated : February 28, 2024
The CADTH Post-Market Drug Evaluation (PMDE) Program launched on September 1, 2022. The program provides evidence-based responses to questions and concerns raised by federal, provincial, and territorial decision-makers about drugs approved for use in Canada.
The PMDE Program brings together a network of external experts in applied research, drug evaluation methodology, and data analysis from across Canada. This network is known as CoLab. It provides timely evidence to answer questions about post-market drug safety and effectiveness. For more information about CoLab, including our Core Network Partners and Network Collaborators, please visit the CoLab website. website.
For additional information on the PMDE Program, please refer to the PMDE Program Overview.
Post-market drug evaluation (PMDE) focuses on drugs that have gone through the regulatory approval process and are broadly available to patients and consumers. PMDE integrates health data and real-world evidence to inform decisions on drug safety and effectiveness and other key regulatory aspects.
The primary goal of the PMDE Program is to establish a network of applied researchers, methodologists, and analysts (together named the CoLab). CoLab answers queries related to post-market drug safety and effectiveness by bringing timely evidence into the hands of decision-makers by:
The PMDE Program provides timely and reliable evidence to decision-makers in Canada, including:
Core Network Partners and Network Collaborators are identified through a request for proposal (RFP) process. The most recent RFP closed in April 2022. To be part of CoLab, please check here every February for new RFPs.
For more information or to get in touch, please email [email protected].
Check back for more exciting news and updates!